Early signs of supply tightening emerging across global medicine supply chains

Recent commentary has suggested that Australia is not currently experiencing a significant increase in medicine shortage notifications.

While this may be accurate from a reporting perspective, it does not reflect how supply chains behave in practice.

Shortage notifications are a lagging indicator. They confirm disruption after it has already occurred.

In our day-to-day operations sourcing medicines internationally, the earliest signals of disruption appear well before any formal notification.

These typically include reduced supplier allocations, partial order fulfilment, longer and less predictable lead times, and increasing complexity in international freight routing.

We are beginning to observe these conditions across a number of supply channels.

At present, these changes are not yet reflected in official shortage data. However, they are consistent with the early stages of supply tightening.

Australia’s buffer stock requirements and supplier management practices can delay the visibility of shortages. While this provides short-term stability, it can also compress the response window once disruptions become more pronounced.

From an operational perspective, this means that waiting for confirmed shortage notifications may limit available options.

Early planning allows for greater flexibility in sourcing, including access to alternative supply pathways and better management of lead times.

Hospitals and healthcare providers may benefit from reviewing forward requirements and engaging early where continuity of supply is critical.

Pro Pharmaceuticals Group continues to monitor global supply conditions and work with healthcare providers to support continuity of access where standard supply channels become constrained.